Ki Young Y Chung

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Antibody-based therapies for colorectal cancer
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 10:701-9. 2005
  2. doi request reprint Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer
    Ki Y Chung
    Gastrointestinal Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:3485-90. 2010
  3. ncbi request reprint Adjuvant therapy of colon cancer: current status and future directions
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021 and Weill Medical College of Cornell University, Ithaca, USA
    Cancer J 13:192-7. 2007
  4. ncbi request reprint Adjuvant Therapy for Stage II Colorectal Cancer: Who and with What?
    Ki Young Y Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Gastroenterol 9:272-80. 2006
  5. ncbi request reprint Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, H 816, New York, NY 10021, USA
    J Clin Oncol 23:1803-10. 2005
  6. ncbi request reprint Cetuximab therapy and symptomatic hypomagnesemia
    Deborah Schrag
    Division of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 221, New York, NY 10011, USA
    J Natl Cancer Inst 97:1221-4. 2005
  7. ncbi request reprint Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 18:1350-6. 2005
  8. ncbi request reprint Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study
    Michael D'Angelica
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 14:759-65. 2007
  9. ncbi request reprint Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells
    Malcolm A S Moore
    Moore Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Exp Hematol 35:105-16. 2007
  10. pmc Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation
    Jan Jacob Schuringa
    Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Exp Med 200:623-35. 2004

Detail Information

Publications12

  1. ncbi request reprint Antibody-based therapies for colorectal cancer
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 10:701-9. 2005
    ..South San Francisco, CA, http://www.gene.com) and cetuximab (Erbitux; ImClone Systems, Inc., New York, http://www.imclone.com), in colorectal cancer...
  2. doi request reprint Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer
    Ki Y Chung
    Gastrointestinal Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:3485-90. 2010
    ..Safety and efficacy of tremelimumab (CP-675,206), a fully human anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) monoclonal antibody, were assessed in patients with treatment-refractory colorectal cancer...
  3. ncbi request reprint Adjuvant therapy of colon cancer: current status and future directions
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021 and Weill Medical College of Cornell University, Ithaca, USA
    Cancer J 13:192-7. 2007
    ....
  4. ncbi request reprint Adjuvant Therapy for Stage II Colorectal Cancer: Who and with What?
    Ki Young Y Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Gastroenterol 9:272-80. 2006
    ....
  5. ncbi request reprint Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, H 816, New York, NY 10021, USA
    J Clin Oncol 23:1803-10. 2005
    ....
  6. ncbi request reprint Cetuximab therapy and symptomatic hypomagnesemia
    Deborah Schrag
    Division of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 221, New York, NY 10011, USA
    J Natl Cancer Inst 97:1221-4. 2005
    ..Because symptoms may be rapidly ameliorated with supplementation, we suggest that, when fatigue or hypocalcemia is encountered during cetuximab therapy, serum magnesium level be measured and repleted as necessary...
  7. ncbi request reprint Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 18:1350-6. 2005
    ..Additional studies are needed to determine whether epidermal growth factor receptor gene amplification bears any informative value in predicting response to cetuximab-based therapy...
  8. ncbi request reprint Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study
    Michael D'Angelica
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 14:759-65. 2007
    ..Perioperative bev is now commonly used in patients undergoing hepatic resection. Little is known, however, about the safety of perioperative bev use in the setting of hepatic resection...
  9. ncbi request reprint Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells
    Malcolm A S Moore
    Moore Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Exp Hematol 35:105-16. 2007
    ..To model human leukemogenesis by transduction of human hematopoietic stem cells (HSC) with genes associated with leukemia and expressed in leukemic stem cells...
  10. pmc Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation
    Jan Jacob Schuringa
    Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Exp Med 200:623-35. 2004
    ..Our data indicate that a persistent activation of STAT5A in human hematopoietic stem and progenitor cells results in their enhanced self-renewal and diverts differentiation to the erythroid lineage...
  11. ncbi request reprint Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis
    Ki Young Chung
    Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 105:77-84. 2005
    ..Flt3-ITD+ acute myeloid leukemia (AML) blasts from patients invariably generated early AG1295-sensitive CAs in MS-5 cocultures, further validating the phenotype observed in transduced CD34+ cells...
  12. ncbi request reprint Regional and systemic chemotherapy for primary hepatobiliary cancers and for colorectal cancer metastatic to the liver
    Ki Young Chung
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Radiat Oncol 15:284-98. 2005
    ..Therefore, the regional approach for hepatobiliary tumors deserves further investigation as well as randomized trials for adequate comparison to new systemic chemotherapies...